PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DR26FQQQ74571382098!keytruda 100 MG 4 ML VIAL 4ml — Dms Pharmaceutical Group Inc

Dms Pharmaceutical Group Inc holds $737.3M across 100,503 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award under parent SPE2DR25D9331. PoP ended Apr 23, 2026 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support
Awarding office
Dms Pharmaceutical Group Inc
Recipient
Apr 23, 2026
PoP end
$175K
Obligated
$175K
Potential
424210
NAICS
6505
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Dms Pharmaceutical Group Inc — $90

Contract facts

Federal
Contract numberSPE2DR26FQQQ7
Also listed asSPE2DR25D9331-SPE2DR26FQQQ7
AgencyDla Troop Support
Awarding officeDla Troop Support
Awarding agencyDepartment of Defense (DOD)
Funding agencyDepartment of Defense (DOD)
IncumbentDms Pharmaceutical Group Inc
CAGE1UNB0
UEIPX72BSBQTKJ3
NAICS424210

No full NAICS 424210 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDVSPE2DR25D9331
Place of performancePARK RIDGE IL
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startApr 2, 2026
PoP end (current)Apr 23, 2026
Obligated$175K
Current value$175K
Potential value$175K

4571382098!KEYTRUDA 100 MG/4 ML VIAL 4ML is a federal award for Dla Troop Support held by Dms Pharmaceutical Group Inc. Estimated value $175K ($175K obligated). Current period of performance ends Apr 23, 2026. Place of performance: PARK RIDGE IL.

Recompete timing

Public
Past PoP end (120 days ago)

Current PoP ended Apr 23, 2026 (120 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Dms Pharmaceutical Group Inc$737.3M obligated across 100,503 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($737.3M) · all agencies
Department of Defense (DOD)$737.1M · 100%Department of Veterans Affairs (VA)$193K · 0%
Open full company profile

Related awards

Same parent · incumbent
SPE2D026F0120
8511978882!OTHER MEDICAL
$248K
Apr 26, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract SPE2DR26FQQQ7?

SPE2DR26FQQQ7 (4571382098!keytruda 100 MG 4 ML VIAL 4ml) is a Dla Troop Support award with a potential value of $175K, currently held by Dms Pharmaceutical Group Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2DR26FQQQ7?

Dla Troop Support awarded SPE2DR26FQQQ7 to Dms Pharmaceutical Group Inc (potential $175K).

Who is the incumbent on SPE2DR26FQQQ7?

Dms Pharmaceutical Group Inc is the incumbent with $737.3M across 100503 related awards in SCOUT’s public footprint. The current period of performance ends Apr 23, 2026.

When does Dms Pharmaceutical Group Inc’s SPE2DR26FQQQ7 come up for recompete?

SCOUT tracks a period-of-performance end of Apr 23, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/SPE2DR26FQQQ7